Printer Friendly

IMMUNOMEDICS' EUROPEAN PATENT SUCCESSFULLY OPPOSED

 IMMUNOMEDICS' EUROPEAN PATENT SUCCESSFULLY OPPOSED
 WARREN, N.J., May 5 /PRNewswire/ -- Immunomedics, Inc.


(NASDAQ: IMMU) announced today that the European Patent Office reversed the prior validation of Immunomedics' patent covering monoclonal antibody fragments used in cancer imaging. In April 1990, the company's patent (EP 35,265) was upheld in an administrative proceeding before the European Patent Office. Corresponding patents issued in the United States, Canada, and certain other countries are not affected by this ruling nor is Immunomedics' right to sell products in Europe influenced by this ruling. While, on the basis of the ruling, the company cannot currently prevent other companies from entering the European market, Immunomedics has various other patents pending in the European Patent Office covering its broad product portfolio in clinical trials and certain products of competitors. These patents include direct labeling of antibodies with technetium and rhenium and certain anti-cancer antibodies. The ruling also does not affect any of these pending patents.
 "This decision was based upon 'prior art' which is not applicable in the U.S. and Canada due to differing patent laws. Consequently, we are confident in the strength of our issued patents in these countries," stated Gilbert W. Rudman, company patent counsel.
 Immunomedics is a biopharmaceutical company applying innovative technology in antibody selection, modification and chemistry to the development of products for the detection and treatment of cancers and infectious diseases. Integral to these products are highly specific monoclonal antibodies designed to deliver radioisotopes, chemotherapeutic agents or toxins to tumors and sites of infections or other diseases.
 -0- 5/5/92
 /CONTACT: Amy Factor of Immunomedics, 908-647-5400/ CO: Immunomedics, Inc. ST: New Jersey IN: MTC SU:


PS-SH -- NY096 -- 6797 05/05/92 17:33 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 5, 1992
Words:283
Previous Article:PRAIRIE OIL ROYALTIES COMPANY LTD. ANNOUNCES FIRST QUARTER RESULTS
Next Article:TREADCO, INC. ANNOUNCES 1992 SECOND QUARTER CASH DIVIDEND


Related Articles
IMMUNOMEDICS RECEIVES BROAD EUROPEAN PATENT FOR HIGHLY SPECIFIC CANCER TARGETING ANTIBODIES
IMMUNOMEDICS IS GRANTED TWO U.S. PATENTS
Immunomedics Awarded U.S. Patent for Therapeutic Conjugates of Toxins and Drugs
Immunomedics Patents New Diagnostic and Therapeutic Agents
Immunomedics Wins Patent in Japan
Dutch court upholds Immunomedics' patent
Immunomedics Defeats Hoffmann-LaRoche Patent Challenge and an Opposition in Japan.
Immunomedics defeats Hoffmann-LaRoche patent challenge and an opposition in Japan.
Dutch Supreme Court sustains Immunomedics patent.
Dutch Supreme Court Sustains Immunomedics Patent; Court Refers Cross-Border Issue to European Court of Justice.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters